Liu Guoqiang, Hong Tianpei, Yang Jin
Department of Endocrinology and Metabolism, Peking University Third Hospital, Beijing 100191, People's Republic of China.
Drug Des Devel Ther. 2020 Aug 21;14:3429-3434. doi: 10.2147/DDDT.S271754. eCollection 2020.
There is no specific and effective medication for coronavirus disease 2019 (COVID-19), and avaccine is not available in recent months. Here, we hypothesize that a single large dose of vitamin D (Vit D) could be an option for trial in COVID-19. Vit D deficiency or insufficiency is very common in the general population as well as in patients with COVID-19. It has been shown that low Vit D level is associated with viral infection, and Vit D supplementation is beneficial for people infected with viruses, such as HIV and hepatitis C virus. Although COVID-19 is a respiratory disease, the morbidity and mortality of this disease are driven by coagulopathy. Clinical studies have shown that Vit D can exert anticoagulant effects. Vit D, a lipid-soluble vitamin, can be administered as a draught. Vit D supplementation is safe and has rare toxic events. In addition, the cost of Vit D is fairly low. Based on these observations, we speculate that a single dose of 300,000 IU Vit D may have a role in the prevention and treatment of COVID-19.
对于2019冠状病毒病(COVID-19),目前尚无特效药物,且近几个月内也没有可用疫苗。在此,我们推测大剂量单次服用维生素D(Vit D)可能是一种可用于COVID-19试验的选择。维生素D缺乏或不足在普通人群以及COVID-19患者中都非常常见。研究表明,低维生素D水平与病毒感染有关,补充维生素D对感染病毒(如艾滋病毒和丙型肝炎病毒)的人有益。尽管COVID-19是一种呼吸道疾病,但该疾病的发病率和死亡率是由凝血病驱动的。临床研究表明,维生素D可发挥抗凝作用。维生素D作为一种脂溶性维生素,可以制成药剂服用。补充维生素D是安全的,且很少发生毒性事件。此外,维生素D的成本相当低。基于这些观察结果,我们推测单次服用300,000国际单位维生素D可能在COVID-19的预防和治疗中发挥作用。